Please ask Malcolm about the NIH grant for Vical's RapidResponse cell-free DNA mfg process. Is this going to be direct competition for CYGX's cell-free DNA process? If so, how is MS going to respond to this? Wait a year or more to build a mfg facility? Form new partnerships? Look at a merger / buyout? It should be interesting to see his response.
Market Data 
Markets 
